Eli Lilly & Company (LLY) Favors Pullback Before Rally Resumes

Eli Lilly & Company (LLY) discovers, develops & markets human pharmaceuticals worldwide. It is having around 550 B market cap as on December, 18th. It is based in Indianapolis, Indiana, US, comes under Healthcare sector & trades as “LLY” ticket at NYSE.

Eli Lilly & Company (LLY) discovers, develops & markets human pharmaceuticals worldwide. It is having around 550 B market cap as on December, 18th. It is based in Indianapolis, Indiana, US, comes under Healthcare sector & trades as “LLY” ticket at NYSE.

LLY reacted higher as expected from the previous article, in ((3)) towards $584.39 or higher levels. It ended ((3)) of III at $629.97 high & favors double correction in ((4)) before rally resumes.

LLY - Elliott Wave Weekly View From 8.14.2023: 

In Weekly sequence, it finished (I) at $92.85 high in September-2015 & (II) at $64.18 low in November-2016. Above there, it favors higher in (III) of ((III)), in which it placed I at $132.13 high & II at $101.36 low. It favors higher in third wave extension in III & expect pullback in ((4)) before rally resumes in ((5)). It placed ((1)) at $375.25 high & ((2)) at $309.20 low. Within ((1)), it finished (1) at $170.75 as diagonal structure & (2) at $129.21 low as 0.618 Fibonacci retracement. It placed (3) at $335.33 high, (4) at $296.32 low & (5) at $375.25 high.

LLY - Elliott Wave Latest Weekly View: 

It ended ((3)) of III at $629.97 high in III. Within ((3)), it placed (1) at $469.87 high, (2) at $434.34 low, (3) at $601.84 high, (4) at $516.57 low & finally (5) as ((3)) at $629.97 high. Currently, it favors pullback in ((4)) as double correction & expect choppiness. It placed (W) at $547.61 low and (X) at $625.87 high. Below there, it favors lower in (Y) of ((4)) towards $543.93 - $492.72 area as blue box. It expects to find the buyers from the blue box area to resume upside in ((5)) to finish III of (III).

Source: https://elliottwave-forecast.com/stock-market/lly-favors-pullback-before-rally-resumes/

Disclaimer: This and other personal blog posts are not reviewed, monitored or endorsed by TalkMarkets. The content is solely the view of the author and TalkMarkets is not responsible for the content of this post in any way. Our curated content which is handpicked by our editorial team may be viewed here.

STOCKS IN THIS BLOG POST

Comments